October 12, 2012
Dave Hinds is a Principal Scientist in Statistical Genetics. 23andMe is passionate about research on a group of rare blood disorders called myeloproliferative neoplasms, or MPNs. Physicians who study these disorders consider them to be blood cancers, though individual prognoses can vary widely — some [...]
September 4, 2012
Dr. Ross Levine Last year 23andMe launched a Myeloproliferative Neoplasms Research Initiative to study this group of rare blood cancers. We are now very close to reaching our goal of enrolling 1,000 patients and are encouraged by what we’ve already learned. We’re also humbled that another star in the [...]
February 29, 2012
Today, February 29, is Rare Disease Day — a concept first initiated by the European Rare Disease Organization (EURORDIS) and now recognized around the world. Join the Global Genes Project™ and help unite one million people for rare diseases. The Global Genes Project™ is a campaign that works [...]
February 27, 2012
February 29th is Rare Disease Day! Fight rare disease by helping us reach 800 participants in our Sarcoma Community and 500 participants in our Myeloproliferative Neoplasms Research Initiative this week. Learn more below. At 23andMe, we believe in fostering individual empowerment and increasing access to [...]
December 28, 2011
We thought 2010 would be hard to top but we’re happy to say that 2011 has been even better. Scientists uncovered new insights into serious conditions like type 2 diabetes and autoimmune disorders as well as traits like iris patterns. New research has also improved our understanding of the genetics of [...]
August 3, 2011
by Ashley Gould Vice President Corporate Development & Chief Legal Officer, 23andMe Linda Avey and Anne Wojcicki created 23andMe based on a number of visions. They described one of these to me in early 2007, capturing my imagination and playing a large role in my decision to become a member of the [...]
